)
MustGrow Biologics (MGRO) investor relations material
MustGrow Biologics Status update summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Market opportunity and positioning
Biologicals market expected to reach ~$20B, with mid-teens CAGR over the next ~5–8 years, within a $380B global market for chemicals, fertilizers and biologicals.
Consumer interest in food production and farmer demand for additional solutions are supporting biologicals’ growth across a broad range of technologies.
TerraMG and TerraSante are positioned as science-backed products; adoption depends on demonstrating field performance and value to growers.
Biologicals are framed as complementary tools in integrated pest management, alongside chemistry, seeds and fertilizers, rather than standalone solutions.
EMEA partnership and market fit
Europe is a priority for biologicals amid stricter regulation, fewer chemical crop-protection options and restrictions on synthetic fertilizers; high-value fruit and vegetable crops are a focus.
Regional consumer demand and regulatory pathways distinguish Europe from North America; local expertise and resources make Bayer a key route into EMEA markets.
Bayer contributes scientific testing, field validation and region-specific regulatory expertise, supporting international development and commercialization.
Bayer sees biologicals as part of farmers’ broader toolkit for crop protection, performance and more responsible food systems; partnerships can help scale solutions to more growers.
TerraMG evaluation and progress
A technical milestone confirmed TerraMG formulation compatibility with European farming practices and standard application equipment, with effective handling and application.
Field studies under real conditions confirmed meaningful disease control, with assessment focused on soil-borne diseases.
Bayer’s nearly two-year pre-partnership evaluation included lab and greenhouse tests, field trials, EU regulatory feasibility and intellectual-property assessment; the commercial agreement followed in Dec 2023.
Bayer highlighted TerraMG’s fit with demand for effective biological alternatives to address nematode-related crop yield and quality losses, particularly in fruits and vegetables.
- TerraSante demand outpaces supply as TerraMG advances through Bayer-backed registration.MGRO
20th International Investment Forum (IIF) - Rapid growth in sustainable agriculture with commercialized biologics and global partnerships.MGRO
Corporate presentation - $1.4M licensing milestone, profit recovery, and 46% sales growth despite margin pressure.MGRO
Q2 2026 - Biological ag products TerraSANTE and TerraMG target rapid growth in a $380B global market.MGRO
Corporate presentation - First TerraSante sales and improved margins highlight Q1-2026 amid production scaling and refocus.MGRO
Q1 2026 - 2025 revenue hit CAD 8.3M as TerraSante sales soared 377%, despite a higher net loss.MGRO
Q4 2025 - Record $3.8M Q1-2025 revenue and 14.3% margin mark pivotal growth post-NexusBioAg acquisition.MGRO
Q1 2025 - Record Q2-2025 revenue and margin growth fueled by surging U.S. TerraSante™ sales.MGRO
Q2 2025 - Gross margin rose to 22.9% in Q3, with strong demand setting up a robust Q4.MGRO
Q3 2025
Next MustGrow Biologics earnings date
Next MustGrow Biologics earnings date
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
)
)